Literature DB >> 15034190

Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?

Samy I McFarlane1, Ranganath Muniyappa, John J Shin, Gul Bahtiyar, James R Sowers.   

Abstract

Both osteoporosis and cardiovascular disease (CVD) are major public health problems leading to increased morbidity and mortality. Although traditionally viewed as separate disease entities that increase in prevalence with aging, accumulating evidence indicates that there are similar pathophysiological mechanisms underlying both diseases. In addition to menopause and advanced age, other risk factors for CVD such as dyslipidemia, oxidative stress, inflammation, hyperhomocystinemia, hypertension, and diabetes have also been associated with increased risk of low bone mineral density (LBMD). Elevated LDL and low HDL cholesterol are associated with LBMD, altered lipid metabolism is associated with both bone remodeling and the atherosclerotic process, which might explain, in part, the co-existence of osteoporosis and atherosclerosis in patients with dyslipidemia. Similarly, inflammation plays a pivotal role in both atherosclerosis and osteoporosis. Elevated plasma homocysteine levels are associated with both CVD and osteoporosis. Nitric oxide (NO), in addition to its known atheroprotective effects, appears to also play a role in osteoblast function and bone turnover. Supporting this notion, in a small randomized controlled trial, nitroglycerine (an NO donor) was found to be as effective as estrogen in preventing bone loss in women with surgical menopause. Statins, agents that reduce atherogenesis, also stimulate bone formation. Furthermore, bis- phosphonates, used in the treatment of osteoporosis, have been shown to inhibit atherogenesis. Intravenous bisphosphonate therapy significantly decreases serum LDL and increases HDL in postmenopausal women The exciting possibilities of newer pharmacological agents that effectively treat both osteoporosis and CVD hold considerable promise. However, it is important to emphasize that the current evidence linking both of these diseases is far from conclusive. Therefore, additional research is necessary to further characterize the relationship between these two common illnesses.

Entities:  

Mesh:

Year:  2004        PMID: 15034190     DOI: 10.1385/ENDO:23:1:01

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  115 in total

1.  Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin.

Authors:  T Wada; M D McKee; S Steitz; C M Giachelli
Journal:  Circ Res       Date:  1999-02-05       Impact factor: 17.367

2.  Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix gla protein in human atherogenesis.

Authors:  M A Engelse; J M Neele; A L Bronckers; H Pannekoek; C J de Vries
Journal:  Cardiovasc Res       Date:  2001-11       Impact factor: 10.787

3.  Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in the female Sprague Dawley rat.

Authors:  C K Schlemmer; H Coetzer; N Claassen; M C Kruger
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1999-12       Impact factor: 4.006

4.  Atherogenic high-fat diet reduces bone mineralization in mice.

Authors:  F Parhami; Y Tintut; W G Beamer; N Gharavi; W Goodman; L L Demer
Journal:  J Bone Miner Res       Date:  2001-01       Impact factor: 6.741

5.  Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women.

Authors:  K K Nicodemus; A R Folsom
Journal:  Diabetes Care       Date:  2001-07       Impact factor: 19.112

6.  Human segmental mandibular defects treated with naturally derived bone morphogenetic proteins.

Authors:  Carlo Ferretti; Ugo Ripamonti
Journal:  J Craniofac Surg       Date:  2002-05       Impact factor: 1.046

7.  Diabetes mellitus as a risk factor for hip fracture in mexican american older adults.

Authors:  Kenneth J Ottenbacher; Glenn V Ostir; M Kristen Peek; James S Goodwin; Kyriakos S Markides
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-10       Impact factor: 6.053

8.  Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits.

Authors:  R Ylitalo; O Oksala; S Ylä-Herttuala; P Ylitalo
Journal:  J Lab Clin Med       Date:  1994-05

9.  Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6.

Authors:  C Miyaura; K Kusano; T Masuzawa; O Chaki; Y Onoe; M Aoyagi; T Sasaki; T Tamura; Y Koishihara; Y Ohsugi
Journal:  J Bone Miner Res       Date:  1995-09       Impact factor: 6.741

10.  Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide.

Authors:  M F Walsh; M Barazi; G Pete; R Muniyappa; J C Dunbar; J R Sowers
Journal:  Endocrinology       Date:  1996-05       Impact factor: 4.736

View more
  85 in total

1.  The association of bone density and calcified atherosclerosis is stronger in women without dyslipidemia: the multi-ethnic study of atherosclerosis.

Authors:  Nicole E Jensky; Joseph A Hyder; Matthew A Allison; Nathan Wong; Victor Aboyans; Roger S Blumenthal; Pamela Schreiner; J Jeffrey Carr; Christina L Wassel; Joachim H Ix; Michael H Criqui
Journal:  J Bone Miner Res       Date:  2011-11       Impact factor: 6.741

2.  Hypercholesterolemia promotes an osteoporotic phenotype.

Authors:  Kristine Pelton; Jaclynn Krieder; Danese Joiner; Michael R Freeman; Steven A Goldstein; Keith R Solomon
Journal:  Am J Pathol       Date:  2012-07-04       Impact factor: 4.307

3.  Fragility Fractures Are Associated with an Increased Risk for Cardiovascular Events in Women and Men with Rheumatoid Arthritis: A Population-based Study.

Authors:  Orla Ni Mhuircheartaigh; Cynthia S Crowson; Sherine E Gabriel; Veronique L Roger; L Joseph Melton; Shreyasee Amin
Journal:  J Rheumatol       Date:  2017-01-15       Impact factor: 4.666

4.  Myocardial infarction risk among patients with fractures receiving bisphosphonates.

Authors:  Cory B Pittman; Lisa A Davis; Angelique L Zeringue; Liron Caplan; Kent R Wehmeier; Jeffrey F Scherrer; Hong Xian; Francesca E Cunningham; Jay R McDonald; Alexis Arnold; Seth A Eisen
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

5.  Ischemic heart disease is associated with lower cortical volumetric bone mineral density of distal radius.

Authors:  J Paccou; M H Edwards; K A Ward; K A Jameson; C L Moss; N C Harvey; E M Dennison; C Cooper
Journal:  Osteoporos Int       Date:  2015-04-24       Impact factor: 4.507

6.  Aortic pulse wave velocity is greater in peritoneal dialysis patients with lower dual energy X-ray absorptiometry (DXA) femoral neck bone mineral density.

Authors:  Kamonwan Tangvoraphonkchai; Andrew Davenport
Journal:  J Nephrol       Date:  2018-12-10       Impact factor: 3.902

7.  Osteoporotic fractures and heart failure in the community.

Authors:  Yariv Gerber; L Joseph Melton; Susan A Weston; Véronique L Roger
Journal:  Am J Med       Date:  2011-05       Impact factor: 4.965

8.  Bone Mineral Density as a Predictor of Atherosclerosis and Arterial Wall Stiffness in Obese African-American Women.

Authors:  Samy I McFarlane; Ghazanfar Qureshi; Gagandeep Singh; Kinda Venner-Jones; Louis Salciccioli; Jason Lazar
Journal:  Cardiorenal Med       Date:  2012-11-24       Impact factor: 2.041

9.  Association of matrix Gla protein gene functional polymorphisms with loss of bone mineral density and progression of aortic calcification.

Authors:  D Tuñón-Le Poultel; J B Cannata-Andía; P Román-García; J B Díaz-López; E Coto; C Gómez; M Naves-Díaz; I Rodríguez
Journal:  Osteoporos Int       Date:  2013-11-27       Impact factor: 4.507

10.  Association between lumbar bone mineral density and vascular stiffness as assessed by pulse wave velocity in postmenopausal women.

Authors:  Miho Mikumo; Hiroya Okano; Remi Yoshikata; Ken Ishitani; Hiroaki Ohta
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.